Special Issue

Advances in Dendritic Cell-Based Delivery Systems

Message from the Guest Editors

Pharmaceutics is excited to announce a Special Issue on "Advances in Dendritic Cell-based Delivery Systems". Dendritic cells (DCs) are potent antigenpresenting cells that play a critical role in modulating the immune response, making them a promising platform for the rapeutic delivery in cancer immunotherapy. infectious diseases, and autoimmune disorders. Recent advancements in dendritic cell-based delivery systems have focused on improving antigen loading, enhancing DC maturation, and optimizing their migration to lymphoid tissues for precise immune activation. Innovations such as nanocarriers, biomaterials, and genetic engineering have further advanced the potential of DC-based therapies, leading to improved efficacy and safety profiles. This Special Issue will explore the latest breakthroughs in dendritic cell delivery systems, including methods for antigen delivery, targeting strategies, and clinical applications. Contributions addressing challenges such as scalability, standardization, and the integration of DC-based systems with other immunotherapeutic approaches are particularly encouraged.

Guest Editors

Dr. Jacqueline Oliva-Ramírez

Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA

Dr. Christian Lehmann

Laboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Hartmannstraße 14, D-91052 Erlangen, Germany

Deadline for manuscript submissions

30 January 2026



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/229620

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

